Cargando…

Is the blood of a surgeon performing HIPEC contaminated by irinotecan, its major metabolites and platinum compounds?

OBJECTIVES: Hyperthermic intraperitoneal chemotherapy (HIPEC) is a beneficial surgical technique for patients, but the surgeons are being exposed to cytotoxic drugs. Few biomonitoring studies were led on blood samples in the context of HIPEC. This study aimed to evaluate the surgeon’s plasmatic and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saint-Lorant, Guillaume, Rodier, Simon, Guilloit, Jean-Marc, Ndaw, Sophie, Melczer, Mathieu, Lagadu, Stéphanie, Palix, Agnès, Delépée, Raphaël
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	De Gruyter 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216843/ https://www.ncbi.nlm.nih.gov/pubmed/34179338 http://dx.doi.org/10.1515/pp-2020-0141

Ejemplares similares

Perception, knowledge and protective practices for surgical staff handling antineoplastic drugs during HIPEC and PIPAC
por: Benoist, Hubert, et al.
Publicado: (2022)

Trace amounts of irinotecan found in the blood of a surgeon after performing HIPEC: what does it imply?
por: Ceelen, Wim
Publicado: (2021)

Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?
por: Batista, Thales Paulo, et al.
Publicado: (2020)

Combination of Irinotecan and a Platinum Agent for Poorly Differentiated Neuroendocrine Carcinomas
por: Ramella Munhoz, Rodrigo, et al.
Publicado: (2013)

Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis
por: Glockzin, Gabriel, et al.
Publicado: (2014)

Occupational Exposure to Antineoplastic Drugs in Twelve French Health Care Setting: Biological Monitoring and Surface Contamination
por: Ndaw, Sophie, et al.
Publicado: (2023)

HIPEC: The Complexities of Clinical Trials
por: Bartlett, David L.
Publicado: (2008)

Bioorthogonal Uncaging of the Active Metabolite of Irinotecan by Palladium‐Functionalized Microdevices
por: Adam, Catherine, et al.
Publicado: (2018)

Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
por: Liu, Ying, et al.
Publicado: (2015)

Cytoreductive Surgery and HIPEC for Regionally Advanced Gallbladder Cancer: a Case Report
por: Huang, Fay, et al.
Publicado: (2022)

Cytoreductive Surgery and HIPEC for Peritoneal Carcinomatosis in the Elderly
por: Spiliotis, J. D., et al.
Publicado: (2014)

The Temperature-Dependent Effectiveness of Platinum-Based Drugs Mitomycin-C and 5-FU during Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Cell Lines
por: Helderman, Roxan F.C.P.A., et al.
Publicado: (2020)

Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane
por: Satake, Hironaga, et al.
Publicado: (2018)

Exceptional response to lurbinectedin and irinotecan in BRCA-mutated platinum-resistant ovarian cancer patient: a case report
por: Cortesi, Laura, et al.
Publicado: (2022)

Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study
por: Petrillo, Marco, et al.
Publicado: (2019)

Cytoreduction and HIPEC in the treatment of “unconventional” secondary peritoneal carcinomatosis
por: Cardi, Maurizio, et al.
Publicado: (2015)

Management of recurrent cervical cancer with peritoneal carcinomatosis with HIPEC
por: Lantsman, Taliya, et al.
Publicado: (2021)

HIPEC for gynaecological malignancies: A last update (Review)
por: Margioula-Siarkou, Chrysoula, et al.
Publicado: (2023)

Surgery and HIPEC in relapse for all patients with ovarian cancer?
por: Hasson, S.P., et al.
Publicado: (2023)

Chemical Imaging of Platinum-Based Drugs and their Metabolites
por: Liu, Xin, et al.
Publicado: (2016)

Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer
por: Park, Ji Soo, et al.
Publicado: (2011)

Multicenter Retrospective Analysis of Chemotherapy for Advanced Pancreatic Acinar Cell Carcinoma: Potential Efficacy of Platinum- and Irinotecan-Containing Regimens
por: Takahashi, Hideaki, et al.
Publicado: (2021)

Sodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC)
por: Muenyi, Clarisse S, et al.
Publicado: (2011)

Comments on: Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study
por: Batista, Thales Paulo, et al.
Publicado: (2019)

Role of HIPEC after Complete Cytoreductive Surgery (CRS) in Peritoneal Recurrence of Platinum-Sensitive Recurrent Ovarian Cancer (OC): The Aim for Standardization at Two Reference Centers for CRS
por: Acs, Miklos, et al.
Publicado: (2023)

Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis
por: Xu, Fei, et al.
Publicado: (2018)

Laparoscopic HIPEC: A bridge between open and closed-techniques
por: Lotti, Marco, et al.
Publicado: (2016)

Bidirectional chemotherapy allowing surgery and HIPEC for malignant peritoneal mesothelioma
por: Noiret, Barbara, et al.
Publicado: (2019)

Efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of malignant ascites
por: Jiao, Jie, et al.
Publicado: (2020)

Conversion Surgery with HIPEC for Peritoneal Oli-gometastatic Gastric Cancer
por: Mielko, Jerzy, et al.
Publicado: (2019)

Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges
por: Helderman, Roxan F. C. P. A., et al.
Publicado: (2021)

Current role for cytoreduction and HIPEC for gastric cancer with peritoneal disease
por: Khan, Hamza, et al.
Publicado: (2022)

Is Routine Omentectomy a Necessary Component of Cytoreductive Surgery and HIPEC?
por: Khan, Sohini, et al.
Publicado: (2022)

DNA Repair Pathway in Ovarian Cancer Patients Treated with HIPEC
por: Flasarova, Dominika, et al.
Publicado: (2023)

Etiological analysis of infection after CRS + HIPEC in patients with PMP
por: Yang, Rui, et al.
Publicado: (2023)

Irinotecan metabolite SN38 results in germ cell loss in the testis but not in the ovary of prepubertal mice
por: Lopes, Federica, et al.
Publicado: (2016)

Effective Irinotecan (CPT‐11)‐containing Liposomes: Intraliposomal Conversion to the Active Metabolite SN‐38
por: Sadzuka, Yasuyuki, et al.
Publicado: (1999)

Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial
por: Qi, Yuwen, et al.
Publicado: (2022)

Tailored-dose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer: a phase II trial
por: Tate, Shinichi, et al.
Publicado: (2020)

Irinotecan-Induced Dysarthria
por: Dressel, Albertine J., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_81ljh4l36qr7b05r8a6snlo2t9